01921nas a2200361   4500000000100000008004100001260001300042653001500055653002400070653001100094653001900105653003800124653001100162653001600173653001100189653002100200653001200221653000900233653002500242653001600267100001500283700001100298700001100309700001600320700001200336700002200348700001400370245010300384300001100487490000800498520103900506022001401545       2010                            d  c2010 Aug10aAdolescent10aAntigens, Bacterial10aBrazil10aChromatography10aEnzyme-Linked Immunosorbent Assay10aFemale10aGlycolipids10aHumans10aImmunoglobulin M10aleprosy10aMale10aMycobacterium leprae10aYoung Adult1 aDa Silva R1 aLyon S1 aLyon A1 aGrossi MA F1 aLyon SH1 aBührer-Sékula S1 aAntunes C00aCorrelation between ELISA and ML Flow assays applied to 60 Brazilian patients affected by leprosy.  a546-500 v1043 a<p>Serological tests can be helpful in classifying leprosy patients as having either the paucibacillary or the multibacillary form. The aim of this study was to evaluate the concordance between two serological assays, i.e. ML Flow and ELISA, in a population of leprosy patients in Brazil. The investigation involved 60 patients with newly diagnosed leprosy. Together with the application of the serological assays, selected demographic, clinical and epidemiological data relating to the study population were recorded. ML Flow detected anti-PGL1 antibodies in 70% of the leprosy patients, while ELISA was positive in 53.3%. The degree of concordance between the tests was substantial (83.3%). A positive correlation was demonstrated between the results obtained in the semi-quantitative ML Flow test and ELISA absorbance values. We concluded that both serological assays were found to be efficient in detecting anti-PGL1 antibodies. The ML Flow test may be a cheaper and easier to perform alternative to ELISA in leprosy patients.</p>  a1878-3503